Results 71 to 80 of about 87,651 (259)

Is There an Equivalence between Measures of Landscape Structural and Functional Connectivity for Plants in Conservation Assessments of the Cerrado?

open access: yesLand, 2020
Landscape connectivity can be assessed based on the physical connection (structural connectivity) or the maintenance of flow among habitats depending on the species (functional connectivity).
Thais Martins Issii   +4 more
doaj   +1 more source

Landscape metrics for determining landscape prices

open access: yes, 2009
This paper reviews the landscape metrics used in economic valuations of farmland and forest landscapes. The diversity of landscape indicators used in the literature (land use, landscape composition, distance from landscape assets, seen landscapes: viewshed, objects, shapes) sometimes leads to divergent results.
Hilal, Mohamed   +5 more
openaire   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Geometric approaches to computing 3D-landscape metrics

open access: yesLandscape Online, 2010
The relationships between patterns and processes lie at the core of modern landscape ecology. These dependences can be quantified by using indices related to the patch-corridor-matrix model.
Mihai Sorin Stupariu   +2 more
doaj   +1 more source

How to calculate landscape metrics for local landscapes?

open access: yes, 2020
In the last few weeks, I was asked a similar question several times - how to calculate landscape metrics for local landscapes? In other words, how to divide the categorical input map into a number of smaller areas, and next calculate selected landscape metrics for each of the areas. Those areas have many names, such as tiles, squares, or motifels.
openaire   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

open access: yesMolecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena   +15 more
wiley   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

Metrics Toolkit: an online evidence-based resource for navigating the research metrics landscape

open access: yesJournal of the Medical Library Association, 2018
While research metrics may seem well established in the scholarly landscape, it can be challenging to understand how they should be used and how they are calculated.
Robin Champieux   +3 more
doaj   +1 more source

Landscape metrics data

open access: yes
Data underlying the landscape metrics figures. Landscape metrics were calculated around each archaeological occurrence using buffers of 5–50 km (Figure4, Figure S2), quantifying suitable area, core area, connectivity, resistance and mean suitability across time.
Masoud Yousefi   +7 more
openaire   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy